{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:26:18Z","timestamp":1787757978630,"version":"build-2784847793"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"\n Japanese encephalitis virus infection manifests as acute encephalitis syndrome leading to significant neurological disability with estimated incidence around 85,000 cases per year and case fatality rate of 30%. Treatment remains largely conservative as there is no specific antiviral available till date. Clinical trials have failed to show the benefit of drugs studied, except minocycline which has some limited evidence. Preclinical studies and\n in silico<\/jats:italic>\n analysis led to identification of various synthetic and natural compounds which could be potential therapies in the future. This article provides an overview of the potential therapeutic options for Japanese encephalitis available in the literature with a description of a case treated to have significant neurological recovery at a resource poor setting.\n <\/jats:p>","DOI":"10.4103\/jvbd.jvbd_179_25","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:00:34Z","timestamp":1780509634000},"page":"275-277","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Minocycline for management of Japanese encephalitis: A case report"],"prefix":"10.4103","volume":"63","author":[{"given":"Naveenraj","family":"Palaniswamy","sequence":"first","affiliation":[{"name":"Department of General Medicine, ESIC Medical College and Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PM","family":"Azarudheen","sequence":"additional","affiliation":[{"name":"Department of General Medicine, ESIC Medical College and Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syam","family":"Unnikrishnan","sequence":"additional","affiliation":[{"name":"Department of Neurology, ESIC Medical College and Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"10","key":"R1-20260604","doi-asserted-by":"crossref","first-page":"e0009385","DOI":"10.1371\/journal.pntd.0009385","article-title":"The current burden of Japanese encephalitis and the estimated impacts of vaccination: Combining estimates of the spatial distribution and transmission intensity of a zoonotic pathogen","volume":"75","author":"Moore","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"R2-20260604","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/j.1471-4159.2008.05238.x","article-title":"Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis","volume":"105","author":"Mishra","year":"2008","journal-title":"J Neurochem"},{"issue":"5","key":"R3-20260604","doi-asserted-by":"crossref","first-page":"371","DOI":"10.17511\/ijpr.2016.i05.18","article-title":"Minocycline trial in japanese encephalitis: a double blind, randomized placebo study","volume":"5","author":"Singh","year":"2016","journal-title":"Pediatr Rev Int J Pediatr Res"},{"issue":"1","key":"R4-20260604","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12879-016-1385-6","article-title":"Role of oral Minocycline in acute encephalitis syndrome in India - a randomized controlled trial","volume":"16","author":"Kumar","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"8","key":"R5-20260604","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/14712598.2018.1499721","article-title":"Recent developments in vaccines and biological therapies against Japanese encephalitis virus","volume":"18","author":"Barzon","year":"2018","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"R6-20260604","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s43440-022-00355-2","article-title":"Antiviral drug research for Japanese encephalitis: an updated review","volume":"74","author":"Joe","year":"2022","journal-title":"Pharmacol Rep"},{"key":"R7-20260604","first-page":"82","article-title":"Natural products and derivatives as Japanese encephalitis virus antivirals","author":"Mi","year":"2024","journal-title":"Pathog Dis"},{"issue":"2","key":"R8-20260604","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/v16020202","article-title":"Current advances in Japanese encephalitis virus drug development","volume":"16","author":"Guo","year":"2024","journal-title":"Viruses"}],"container-title":["Journal of Vector Borne Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jvbd.jvbd_179_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:00:43Z","timestamp":1787756443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jvbd.jvbd_179_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jvbd.jvbd_179_25","relation":{},"ISSN":["0972-9062"],"issn-type":[{"value":"0972-9062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-06-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}